<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">The PREOPANC-2 trial is a multicenter randomized phase III superiority trial, initiated by the Dutch Pancreatic Cancer Group (DPCG). A list of all participating centers is added as 
 <xref rid="MOESM1" ref-type="media">Supplementary file</xref>. Eligible patients are randomly assigned to either receive neoadjuvant FOLFIRINOX followed by surgery without adjuvant treatment (intervention; arm A) or neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine (comparator; arm B) (Fig.Â 
 <xref rid="Fig1" ref-type="fig">1</xref>). Randomization in a 1:1 ratio is performed centrally using a web-based system, with stratification according to center and by resectability status (resectable vs. borderline resectable). 
</p>
